Northwest Biotherapeutics, Inc. filed its 10-K on Mar 01, 2022 for the period ending Dec 31, 2021. In this report its auditor, Cherry, Bekaert & Holland, LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.466 USD | -4.90% | +3.67% | -33.52% |
05-10 | Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-21 | Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors | CI |
1st Jan change | Capi. | |
---|---|---|
-33.52% | 594M | |
+18.72% | 123B | |
+14.53% | 107B | |
-2.88% | 24.01B | |
+2.18% | 22.59B | |
-10.09% | 18.16B | |
-41.04% | 16.84B | |
-11.83% | 16.23B | |
+1.46% | 13.43B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- NWBO Stock
- News Northwest Biotherapeutics, Inc.
- Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt